¿Emergencia médica?¿Emergencia? Llame al 911. Salas de emergencias más cercanasEmergencias cercanas

Medicamento con receta · hay genérico

Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous

Datos oficiales de la FDA, no son consejos

Todo lo que aparece aquí viene de la Administración de Alimentos y Medicamentos de los EE. UU. (FDA): la etiqueta del medicamento, el directorio NDC, Drugs@FDA, los informes de retiros y la lista de escasez. Cada dato indica su fuente y su fecha.

Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.

En una emergencia, llame al 911. Si alguien pudo haber tomado demasiado de un medicamento, llame a la Línea de Ayuda para Envenenamientos (Poison Help): 1‑800‑222‑1222.

Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous: datos clave

Se usa para
En inglés, según la etiqueta: Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults. (fuente)
Con receta o sin receta
Con receta (Rx)
Hay genérico
Sí
Último retiro de la FDA
Ninguno registrado

Fuentes: etiqueta de la FDA (30 de enero de 2024); directorio NDC de la FDA (13 de noviembre de 2026); informes de retiros de la FDA (10 de noviembre de 2026). No es un consejo médico.

Respuestas rápidas

¿Para qué se usa Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous?
La etiqueta aprobada por la FDA (Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc., 30 de enero de 2024) dice, en inglés: “Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults. Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets are an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults.” Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Cuáles son los efectos secundarios de Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous?
La sección «Adverse Reactions» (reacciones adversas) de la etiqueta de la FDA (Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc., 30 de enero de 2024) comienza así, en inglés: «The following serious or otherwise important adverse reactions for bowel preparations are described elsewhere in the labeling: Renal Disease, Acute Phosphate Nephropathy, and Electrolyte Disorders [see Warnings and Precautions (5.1)] Cardiac Arrhythmias [see Warnings and Precautions (5.2)] Seizures [see Warnings and Precautions (5.3)] Use in Patients with Significant Gastrointestinal Disease [see Warnings and Precautions (5.4)] Colonic Mucosal Ulceration and Inflammatory Bowel Disease [see Warnings and Precautions (5.5)] Aspiration [see Warnings and Precautions (5.6)] Hypersensitivity Reactions [see Warnings and Precautions (5.7)] Most common adverse reactions (≥3%) are: bloating, nausea, abdominal pain, and vomiting.» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Qué interacciones tiene Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous?
La sección «Drug Interactions» (interacciones) de la etiqueta de la FDA (Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc., 30 de enero de 2024) comienza así, en inglés: «Drugs that increase risks due to fluid and electrolyte changes.» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous tiene una advertencia en recuadro?
Sí. La etiqueta de la FDA de Monobasic Sodium Phosphate and Dibasic Sodium Phosphate tiene una advertencia en recuadro («WARNING: ACUTE PHOSPHATE NEPHROPATHY»), la advertencia más seria de la FDA. Léala en la etiqueta completa y pregunte a su farmacéutico.
¿Hay escasez de Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous?
La FDA no indica una escasez actual para los productos de este medicamento (datos de la FDA del 13 de noviembre de 2026).
¿Se ha retirado del mercado Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous?
No aparece ningún retiro vinculado a los productos de este medicamento en los informes de la FDA que usamos.
¿Quién fabrica Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous?
5 empresas tienen productos con receta de Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous en el directorio NDC de la FDA, entre ellas American Regent, Inc., Fresenius Kabi USA, LLC y Hospira, Inc.

Para qué se usa Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous

Cita de la sección «Indications and Usage» (indicaciones y uso) de la etiqueta aprobada por la FDA. Se muestra en inglés, tal como la publica la FDA.

Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults. Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets are an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults.

— Etiqueta de la FDA: Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc., vigente desde el 30 de enero de 2024. Leer la etiqueta completa en DailyMed →

Etiqueta citada: la de la presentación más común (tablet, oral), Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc.; abarca 1 producto del directorio NDC de la FDA. Las citas sobre efectos secundarios, interacciones, dosis y embarazo de abajo vienen de esta misma etiqueta.

La FDA tiene 4 etiquetas para productos de este medicamento (distintos fabricantes y presentaciones); los usos pueden variar. Revise la etiqueta de su propio medicamento.

Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.

Advertencia en recuadro

La advertencia en recuadro («caja negra») es la advertencia más seria de la FDA en la etiqueta de un medicamento, para riesgos graves o mortales.

Esta etiqueta tiene una advertencia en recuadro. Su título: WARNING: ACUTE PHOSPHATE NEPHROPATHY. Leerla en la etiqueta completa →

1 de 4 etiquetas de la FDA de este medicamento tienen advertencia en recuadro.

Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous: lo que dice la advertencia en recuadro

Cita de la advertencia en recuadro (Boxed Warning) de la etiqueta aprobada por la FDA. Se muestra en inglés.

WARNING: ACUTE PHOSPHATE NEPHROPATHY There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products, including Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets, for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis [see Warnings and Precautions (5.1)].

Leer más de esta sección

While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1)]. Advise patients of the importance of following the recommended split dosage regimen and the importance of adequate hydration before, during and after the use of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets. Avoid additional sodium phosphate- based purgative or enema products [see Dosage and Administration (2.1, 2.2)]. WARNING: ACUTE PHOSPHATE NEPHROPATHY See full prescribing information for complete boxed warning. Rare, serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products, including Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets, for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. (5.1) Patients at increased risk include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]). (5.1) Advise patients of the importance of following the recommended split dosage regimen and the importance of adequate hydration before, during and after the use of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets. Avoid additional sodium phosphate-based products. (2.1, 2.2)

— Etiqueta de la FDA: Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc., vigente desde el 30 de enero de 2024. Leer la etiqueta completa en DailyMed →

Efectos secundarios de Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous

Cita de la sección «Adverse Reactions» (reacciones adversas) de la etiqueta aprobada por la FDA. Se muestra en inglés. Avise a su médico de cualquier efecto secundario que le preocupe.

The following serious or otherwise important adverse reactions for bowel preparations are described elsewhere in the labeling: Renal Disease, Acute Phosphate Nephropathy, and Electrolyte Disorders [see Warnings and Precautions (5.1)] Cardiac Arrhythmias [see Warnings and Precautions (5.2)] Seizures [see Warnings and Precautions (5.3)] Use in Patients with Significant Gastrointestinal Disease [see Warnings and Precautions (5.4)] Colonic Mucosal Ulceration and Inflammatory Bowel Disease [see Warnings and Precautions (5.5)] Aspiration [see Warnings and Precautions (5.6)] Hypersensitivity Reactions [see Warnings and Precautions (5.7)] Most common adverse reactions (≥3%) are: bloating, nausea, abdominal pain, and vomiting.

Leer más de esta sección

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals Inc. at 1-866-403-7592 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets was evaluated in two randomized, investigator-blinded, active controlled trials in 931 adult patients undergoing elective colonoscopy. The mean age of the study population was 60 years (range 20 to 89 years), 88% of patients were Caucasian and 55% were female [see Clinical Studies (14)]. Table 1 shows the most common adverse reactions reported in greater than 3% of patients by treatment group in Study 1 [see Clinical Studies (14)]. Since diarrhea was considered as a part of the efficacy of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets, diarrhea was not defined as an adverse event in this clinical trial. 1 Reported in more than 3% of patients in at least one treatment group 2 Another oral formulation of monobasic sodium phosphate and dibasic sodium phosphate Table 1: Common Adverse Reactions 1 in Patients Undergoing Colonoscopy in Study 1 Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets 32 tabs (48 g) N=272 Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets 40 tabs (60 g) N=265 Sodium Phosphate2 40 tabs (60 g) N=268 Bloating 31% 39% 41% Nausea 26% 37% 30% Abdominal Pain 23% 24% 25% Vomiting 4% 10% 9% Electrolyte Abnormalities in Study 1 Hyperphosphatemia A total of, 96%, 96%, and 93% of patients who took 60 grams of oral sodium phosphate, 60 grams of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets, and 48 grams of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets, respectively, developed hyperphosphatemia (defined as phosphate level > 5.1 mg/dL) on the day of the colonoscopy. In this study, patients who took 60 grams of oral sodium phosphate, 60 grams of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets, and 48 grams of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets had baseline mean phosphate levels of 3.5, 3.5, and 3.6 mg/dL and subsequently developed mean phosphate levels of 7.6, 7.9, and 7.1 mg/dL, respectively, on the day of the colonoscopy.

— Etiqueta de la FDA: Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc., vigente desde el 30 de enero de 2024. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Interacciones de Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous

Cita de la sección «Drug Interactions» (interacciones) de la etiqueta aprobada por la FDA. Se muestra en inglés. Dígale a su farmacéutico todos los medicamentos, vitaminas y productos herbales que toma.

Drugs that increase risks due to fluid and electrolyte changes.

Leer más de esta sección

(7.1) See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets for patients with conditions, or who are using medications, that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or prolonged QT in the setting of fluid and electrolyte abnormalities. Consider additional patient evaluations as appropriate in patients taking these concomitant medications [see Warnings and Precautions (5.1,5.2,5.3)]. 7.2 Potential for Reduced Drug Absorption Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets can reduce the absorption of other coadministered oral medications. Administer oral medications at least 1 hour before or 1 hour after starting each Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets dose [see Dosage and Administration (2.1)]. 7.3 Other Sodium Phosphate-Based Laxatives Administration of additional sodium phosphate-based purgative or enema products with Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets may increase the risk of acute phosphate nephropathy. Avoid concomitant use [see Warnings and Precautions (5.1)].

— Etiqueta de la FDA: Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc., vigente desde el 30 de enero de 2024. Leer la etiqueta completa en DailyMed →

Dosis de Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous

Cita de la sección «Dosage and Administration» (dosis y administración) de la etiqueta aprobada por la FDA. Se muestra en inglés. Su dosis es la que le receta su médico: no la cambie por su cuenta.

Important Administration Instructions: Two doses of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets are required for a complete preparation for colonoscopy: the first dose the evening before the colonoscopy and the second dose on the morning of the colonoscopy. (2.1) Do not take other laxatives, particularly additional sodium phosphate- based purgative or enema products. (2.1, 7.3) Do not take oral medications within 1 hour before or after starting each dose.

Leer más de esta sección

(2.1, 7.2) Dosage Regimen (2.2) The recommended adult dosage is 32 tablets taken orally with a total of 2 quarts of clear liquids in the following manner: Evening before colonoscopy: 4 tablets with 8 ounces of clear liquids every 15 minutes for a total of 20 tablets. Next morning: 4 tablets with 8 ounces of clear liquids every 15 minutes for a total of 12 tablets. 2.1 Important Administration Instructions Correct fluid and electrolyte abnormalities before treatment with Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets [see Warnings and Precautions (5.1)]. Clear liquids must be consumed before, during and after taking Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets [see Dosage and Administration (2.1), Warnings and Precautions (5.1)]. Do not administer Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets within 7 days of a previous use. Two doses of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets are required for a complete preparation for colonoscopy: the first dose the evening before the colonoscopy and the second dose on the morning of the colonoscopy [see Dosage and Administration (2.2)]. Consume only clear liquids (no solid food) from the start of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets treatment until after the colonoscopy. Do not eat or drink alcohol, milk, anything colored red or purple or any other foods containing pulp material. Do not take other laxatives while taking Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets, particularly additional sodium phosphate-based purgative or enema products [see Drug Interactions (7.3)]. Do not take oral medications within 1 hour before or after starting each dose of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets [see Drug Interactions (7.2)]. 2.2 Dosage Regimen Instruct adult patients that on the day before their colonoscopy, they can consume a light breakfast consisting of clear soup and/or plain yogurt (no solid foods) before noon, followed by only clear liquids until after the colonoscopy. The recommended dose of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets for colon cleansing for adult patients is 32 tablets (48 grams of sodium phosphate) taken orally with a total of 2 quarts of clear liquids in the following manner: The evening before the colonoscopy: Take 4 Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets with 8 ounces of clear liquids every 15 minutes for a total of 20 tablets. On the day of the colonoscopy starting 3 to 5 hours before the procedure: Take 4 Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets with 8 ounces of clear liquids every 15 minutes for a total of 12 tablets.

— Etiqueta de la FDA: Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc., vigente desde el 30 de enero de 2024. Leer la etiqueta completa en DailyMed →

Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous en el embarazo

Cita de la parte sobre embarazo (Pregnancy) de la etiqueta aprobada por la FDA. Se muestra en inglés. Pregunte a su médico antes de tomar cualquier medicamento si está embarazada o planea estarlo.

Risk Summary There are no available data on sodium phosphate use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Animal reproduction studies have not been conducted with sodium phosphate. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.

Leer más de esta sección

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

— Etiqueta de la FDA: Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc., vigente desde el 30 de enero de 2024. Leer la etiqueta completa en DailyMed →

Cuándo no se debe usar Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous

Cita de la sección «Contraindications» (contraindicaciones) de la etiqueta aprobada por la FDA. Se muestra en inglés.

Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets are contraindicated in the following conditions: History of acute phosphate nephropathy [see Warnings and Precautions (5.1)] Gastrointestinal (GI) obstruction [see Warnings and Precautions (5.7)] Gastric bypass or stapling surgery Bowel perforation Toxic colitis Toxic megacolon Hypersensitivity to sodium phosphate salts or any component of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets [see Warnings and Precautions (5.7)].

Leer más de esta sección

Biopsy-proven acute phosphate nephropathy (4, 5.1) Gastrointestinal (GI) obstruction (4, 5.7) Gastric bypass or stapling surgery (4) Bowel perforation (4) Toxic colitis (4) Toxic megacolon (4) Hypersensitivity to sodium phosphate salts or any components of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets (4, 5.7)

— Etiqueta de la FDA: Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc., vigente desde el 30 de enero de 2024. Leer la etiqueta completa en DailyMed →

Sobredosis de Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous

Cita de la sección «Overdosage» (sobredosis) de la etiqueta aprobada por la FDA. Se muestra en inglés. Si alguien pudo haber tomado demasiado, llame a Poison Help al 1-800-222-1222 (o al 911 en una emergencia).

Overdosage of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Tablets may lead to severe electrolyte disturbances, including hyperphosphatemia, hypocalcemia, hypernatremia, or hypokalemia, as well as dehydration and hypovolemia, with attendant signs and symptoms of these disturbances. Certain severe electrolyte disturbances resulting from overdose may lead to cardiac arrhythmias, seizure, renal failure, and death [see Warnings and Precautions (5.1, 5.2, 5.3)].

Leer más de esta sección

Monitor for fluid and electrolyte disturbances and treated symptomatically.

— Etiqueta de la FDA: Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc., vigente desde el 30 de enero de 2024. Leer la etiqueta completa en DailyMed →

Presentaciones y vía de administración

Formas farmacéuticasInyección, solución · Tableta
VíaIntravenosa · Oral
Productos con receta9 en el directorio NDC de la FDA
Nombres de marcaSodium Phosphates

Empresas que tienen este medicamento

Empresas en el directorio NDC de la FDA: la empresa que aparece en el envase (fabricante o distribuidor), con su número de productos con receta.

Historial de aprobación de la FDA

  • NDA: Solicitud de nuevo medicamento (NDA): así se aprueba un medicamento nuevo, normalmente de marca.
  • ANDA: Solicitud abreviada (ANDA): así se aprueba una versión genérica.
Solicitudes de marca y biológicas
SolicitudPatrocinadorAprobadaCambios aprobados después
NDA018892
SODIUM PHOSPHATES IN PLASTIC CONTAINER
Hospira10 de mayo de 1983 22, el último 30 de noviembre de 2023
2023: Fabricación (CMC) · 2023: Fabricación (CMC) · 2015: Fabricación (CMC)

Aprobaciones de genéricos (3)

Escasez

La lista de escasez de la FDA no incluye estos productos.

Base de datos de escasez de medicamentos de la FDA →

Retiros del mercado

No aparece ningún retiro vinculado a estos productos (por su código NDC) en los informes de la FDA.

Identificadores oficiales

RxCUI (RxNorm)1872384, 1872443, 1872447
ID (SPL set ID) de la etiqueta citadae2fcc382-6fac-4438-ad02-ebc8528dd59a
Etiquetas de la FDA (SPL)4
Solicitudes de la FDANDA018892, 3 ANDA
Principios activos (FDA)SODIUM PHOSPHATE, DIBASIC, ANHYDROUS / SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

Siguientes pasos

Fuentes

  1. Etiqueta aprobada por la FDA en DailyMed (Biblioteca Nacional de Medicina) — Monobasic Sodium Phosphate and Dibasic Sodium Phosphate, Lupin Pharmaceuticals,Inc., vigente desde el 30 de enero de 2024; vía openFDA, datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  2. NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  3. Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  4. Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 10 de noviembre de 2026, consultados el 14 de noviembre de 2026
  5. Drug shortages (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026

La FDA ofrece los datos de openFDA tal cual; pueden estar incompletos. Guíese siempre por la etiqueta que viene con su medicamento. Buscador de informes de retiros de la FDA →

Informar un error → · Información para fabricantes de medicamentos